



Does Your Child Have **PRIMARY IMMUNODEFICIENCY DISEASE?**

Primary Immunodeficiency Disease (PIDD) is a condition that impairs the immune system and many people with PIDD receive immunoglobulin treatment as a replacement therapy. The purpose of this study is to evaluate the safety and effectiveness of ASCENIV™, an FDA approved IVIG therapy when given to patients ages 2-11 with Primary Immunodeficiency Disease.

Qualified Participants Must:

- Be male or female patients between 2 and 11 years of age.
- Must have a diagnosis of primary immunodeficiency disease.
- Received IGIV therapy maintained at a steady dose for at least 3 months prior to screening.

ADDITIONAL CRITERIA APPLY

Qualified Participants May:

- Have access to first-in-class care to treat PIDD.
- See a doctor or medical staff for study related visits at no cost.
- Receive compensation for time and travel.

